Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NWY001 in advanced solid tumors
NCT05979155Phase 1Recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of NWY001 in solid tumor, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 5 more (2 arms), sponsored by Akeso, Inc. Primary endpoints: Dose-limiting toxicity at 21 days and Incidence of adverse events. Started Jan 2024; status: recruiting.
02
Drugs
NWY001
03
Conditions
solid tumorgastric adenocarcinomagastroesophageal junction adenocarcinomaEsophageal Squamous Cell Carcinoma (ESCC)pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT05979155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05979155.